BRIEF-BioXcel Therapeutics Says Phase 2A Trial Enrollment Expected In H1 2025

Reuters10-15

Oct 15 (Reuters) - BioXcel Therapeutics Inc :

* BIOXCEL THERAPEUTICS ANNOUNCES U.S. DEPARTMENT OF DEFENSE GRANT TO UNIVERSITY OF NORTH CAROLINA TO FUND STUDY OF BXCL501 (SUBLINGUAL DEXMEDETOMIDINE) FOR TREATING ACUTE STRESS DISORDER

* BIOXCEL THERAPEUTICS INC - PHASE 2A TRIAL ENROLLMENT EXPECTED IN H1 2025

* BIOXCEL THERAPEUTICS INC - DOD AWARDS $2.8 MILLION TO UNC FOR BXCL501 TRIAL

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475571333?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-15 19:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475571333","market":"us","top_or_hot":-1,"title":"BRIEF-BioXcel Therapeutics Says Phase 2A Trial Enrollment Expected In H1 2025","media":"Reuters","content":"<html><body><p>Oct 15 (Reuters) - BioXcel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * BIOXCEL THERAPEUTICS ANNOUNCES U.S. DEPARTMENT OF DEFENSE GRANT TO UNIVERSITY OF NORTH CAROLINA TO FUND STUDY OF BXCL501 (SUBLINGUAL DEXMEDETOMIDINE) FOR TREATING ACUTE STRESS DISORDER</p><p>   * BIOXCEL THERAPEUTICS INC - PHASE 2A TRIAL ENROLLMENT EXPECTED IN H1 2025</p><p>   * BIOXCEL THERAPEUTICS INC - DOD AWARDS $2.8 MILLION TO UNC FOR BXCL501 TRIAL</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-BioXcel Therapeutics Says Phase 2A Trial Enrollment Expected In H1 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-BioXcel Therapeutics Says Phase 2A Trial Enrollment Expected In H1 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-15 19:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 15 (Reuters) - BioXcel Therapeutics Inc   :   * BIOXCEL THERAPEUTICS ANNOUNCES U.S. DEPARTMENT OF DEFENSE GRANT TO UNIVERSITY OF NORTH CAROLINA TO FUND STUDY OF BXCL501 (SUBLINGUAL DEXMEDETOMIDINE...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2475571333","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475571333","pubTimestamp":1728990706,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 15  - BioXcel Therapeutics Inc   :   * BIOXCEL THERAPEUTICS ANNOUNCES U.S. DEPARTMENT OF DEFENSE GRANT TO UNIVERSITY OF NORTH CAROLINA TO FUND STUDY OF BXCL501  FOR TREATING ACUTE STRESS DISORDER   * BIOXCEL THERAPEUTICS INC - PHASE 2A TRIAL ENROLLMENT EXPECTED IN H1 2025   * BIOXCEL THERAPEUTICS INC - DOD AWARDS $2.8 MILLION TO UNC FOR BXCL501 TRIALSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BTAI":"Bioxcel Therapeutics Inc.","LENZ":"Therapeutics"},"translate_title":"简介-BioXcel Therapeutics表示2A期试验预计将于2025年上半年进行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"BTAI":0.9},"content_text":"Oct 15 (Reuters) - BioXcel Therapeutics Inc   :   * BIOXCEL THERAPEUTICS ANNOUNCES U.S. DEPARTMENT OF DEFENSE GRANT TO UNIVERSITY OF NORTH CAROLINA TO FUND STUDY OF BXCL501 (SUBLINGUAL DEXMEDETOMIDINE) FOR TREATING ACUTE STRESS DISORDER   * BIOXCEL THERAPEUTICS INC - PHASE 2A TRIAL ENROLLMENT EXPECTED IN H1 2025   * BIOXCEL THERAPEUTICS INC - DOD AWARDS $2.8 MILLION TO UNC FOR BXCL501 TRIALSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475571333"}